rAAV Production Using Split Adenoviral Rep and Cap Vectors
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing methods for producing recombinant adeno-associated virus (rAAV) vectors are limited by low yields, high costs, and inefficiencies in scaling up production, particularly for clinical applications requiring large quantities of highly-purified vector particles.
Innovation Solution
A method involving the use of separate recombinant adenoviral vectors expressing AAV Rep and Cap proteins, without the RIS-Ad sequence, to infect cells and produce rAAV vectors, utilizing a heterologous promoter like HSV-TK to enhance replication and stability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If traditional co-transfection of HEK293 cells with vector and helper plasmids is used, then rAAV vectors can be produced, but production yields are limited and scaling up is inefficient
Solution Approach 1:
The invention divides the production system into three separate recombinant adenoviral vectors: one providing Rep proteins, one providing Cap proteins, and one providing the transgene flanked by ITRs. This segmentation allows each component to be optimized independently and eliminates the limitations of plasmid co-transfection, enabling scalable production with yields exceeding 10^12 vector particles per liter of culture.
Solution Approach 2:
The invention uses recombinant adenoviruses as intermediary vectors to deliver the necessary components (Rep, Cap, and transgene) to the packaging cells. These adenoviral vectors serve as efficient mediators that can infect cells and establish stable expression of the required elements, overcoming the inefficiencies of direct plasmid transfection and enabling high-yield production.
2Quantity of substance
If large quantities of rAAV vectors are produced for clinical applications, then patient treatment requirements are met, but production costs increase and purification complexity increases
Solution Approach 1:
The recombinant adenoviral vectors used in this invention serve multiple functions: they deliver genetic material to packaging cells, establish stable expression of Rep and Cap proteins, and provide the transgene for packaging. This multi-functionality reduces the number of separate components needed, simplifies the production process, and enables cost-effective scaling to clinical quantities without proportionally increasing purification complexity.
3Stability of the object's composition
If stable production systems are established for rAAV vectors, then consistent quality is achieved, but production efficiency and scalability are limited
Solution Approach 1:
By segmenting the production system into separate adenoviral vectors for Rep, Cap, and transgene delivery, the invention achieves stable production through controlled, independent expression of each component. This segmentation allows each vector to be optimized for stability while the system as a whole achieves high scalability, producing over 10^12 vector particles per liter without compromising composition consistency.
Data Source
AI summary
The present invention is directed to novel production methods for recombinant adeno-associated viral (AAV) vectors or AAV virus-like particles for use in research as well as therapeutic applications. In particular, the invention discloses an advantageous method for producing recombinant adeno-associated virus (rAAV) vectors or AAV virus-like particles wherein a cell is infected with a first recombinant adenoviral vector encoding the AAV Rep proteins, and a second recombinant adenoviral vector encoding the AAV Cap proteins. The cell is further provided with a transgene-vector harboring an expression cassette flanked by AAV inverted terminal repeats (ITRs) comprising a transgene. The invention further discloses a kit or a composition for producing an rAAV vector according to the method of the invention that comprises the transgene vector, the first recombinant adenoviral vector encoding the AAV Rep proteins, and the second recombinant adenoviral vector encoding the AAV Cap proteins. The method, kits and composition of the invention allow for an increased production of AAV vector particles in a stable system.